Core Insights - The company achieved record full-year revenue of $3.9 million, driven by significant second-half momentum and a 92% increase in fourth-quarter revenue compared to the prior year [1] - Performance was primarily propelled by growth in surgical procedure volumes across both Catamaran and SImmetry+ platforms, fueled by new physician adoption [1] - The company transitioned from a single-product provider to a multi-solution organization following the SiVantage transaction, allowing it to address diverse patient anatomies and surgeon preferences [1] Financial Performance - Improved gross margins to 69% in the fourth quarter through operational effectiveness initiatives, better field productivity, and increased leverage of commercial infrastructure [1] - Enhanced financial flexibility through a $2.85 million ATM PIPE and a subsequent $4.3 million private placement of senior convertible notes to fund commercial expansion [1] Intellectual Property - Strengthened the intellectual property estate to 29 issued U.S. patents and 31 pending applications, reinforcing the defensibility of both core technologies [1]

Core Insights - The company has strengthened its financial position through a $2.85 million At-The-Market PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, aimed at supporting commercial expansion and product launches [1][12] - Tenon Medical achieved FDA 510(k) clearance for the SImmetry+ SI-Joint Fusion System, enhancing its product portfolio and enabling broader market adoption [2][6] - The company reported record full-year revenue of $3.9 million for 2025, a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, representing a 92% increase year-over-year [4][8] Financial Performance - Revenue for the fourth quarter of 2025 was $1.5 million, up 92% from $0.8 million in Q4 2024, driven by increased surgical procedures across both Catamaran and SImmetry+ platforms [8][9] - Gross profit for Q4 2025 was $1 million, or 69% of revenue, compared to $0.4 million or 46% in the prior year, marking a 188% increase and a 23 percentage point improvement in gross margin [9][10] - Operating expenses for Q4 2025 totaled $3.9 million, up from $3.5 million in the prior year, while net loss for the quarter was $2.8 million, an improvement from a net loss of $3.1 million in Q4 2024 [11][12] Strategic Initiatives - The company has expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its total to 29 issued U.S. patents and 31 pending applications [5] - Tenon Medical is focused on optimizing its cost structure and scaling operations to enhance market reach and drive revenue growth, particularly with the recent launch of SImmetry+ [6][14] - The company aims to deepen physician engagement and accelerate adoption of its products, leveraging the momentum from its recent FDA clearance and expanding product offerings [6][21] Market Position and Future Outlook - The company believes it is well-positioned for sustained growth in 2026, supported by a multiproduct portfolio that addresses various surgical needs and preferences [5][21] - Tenon Medical anticipates continued revenue growth driven by the commercialization of SImmetry+ and other products in its pipeline, with a strong focus on execution and market expansion [19][20] - The company is optimistic about its ability to meet and exceed expectations in 2026, citing high adoption rates and positive feedback from early clinical cases [18][19]

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million or 69% of revenue, compared to $0.4 million or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter of 2025, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement and adoption [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][7] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is committed to advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The focus is on optimizing the cost structure and scaling operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline of products [22][28] - The company aims to address various patient needs and physician preferences with a multi-product portfolio, enhancing its competitive position in the market [33] Other Important Information - The company strengthened its financial position through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 rate of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [17][18] Question: What is the revenue outlook for 2026 relative to the $6 million run rate? - Management expressed excitement about adoption momentum and the impact of new product launches on revenue growth in 2026, although they do not provide specific projections [19][21][25] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers, with a focus on addressing various patient and physician needs [27][28] Question: How is the launch of SImmetry+ impacting access to physicians? - Management noted that the broader portfolio allows for multiple solutions, opening doors to more physicians and medical centers, with positive feedback on the SImmetry+ technology [32][34]

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million, or 69% of revenue, compared to $0.4 million, or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][8] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is focused on advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The company aims to optimize its cost structure and scale operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline [22][24] - The company believes that its multi-product portfolio will address various physician and patient needs, enhancing its competitive position in the market [30] Other Important Information - The company strengthened its balance sheet through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 operating expense of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [18][19] Question: What is the revenue outlook for 2026? - Management did not provide specific projections but expressed excitement about adoption momentum and the impact of new product launches on revenue growth [22][24][28] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers for revenue growth, with a focus on addressing various physician needs [30][39]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $564,000, down from $901,000 in the same period last year, with a six-month revenue of $1,300,000 compared to $1,600,000 in the prior year [9] - Gross profit was $245,000 or 43% of revenue in Q2 2025, compared to $470,000 or 52% of revenue in the prior year quarter, with a six-month gross profit of $568,000 or 44% of revenue compared to $940,000 or 58% in the previous year's period [10] - Operating expenses totaled $3,100,000 in Q2 2025, down from $4,300,000 in the prior year period, reflecting a 29% reduction driven by lower expenses across various departments [11] - Net loss for Q2 was $2,800,000 or $0.36 per share, compared to a net loss of $3,800,000 or $8.16 per share in 2024, with a six-month net loss of $6,400,000 compared to $7,400,000 in the same year-ago period [12] Business Line Data and Key Metrics Changes - The Catamaran platform is advancing with real-world adoption in complex spine procedures, supported by FDA clearance for uses in thoracolumbar fixation [4] - The Catamaran SE, a second-generation low-profile implant, is on track for full commercial launch in the coming weeks, with positive feedback from alpha reviews [4] - The company is preparing for initial alpha surgeries using the newly developed Symmetry Plus system, expected to begin in Q4 2025 [5] Market Data and Key Metrics Changes - The strategic acquisition of SciVantage enhances the company's commercial organization and market access, providing new pathways through hospital approval processes and distribution networks [3] - The acquisition is expected to increase active case volume and revenue-generating technologies, contributing to the company's growth trajectory [2] Company Strategy and Development Direction - The company is focused on delivering solutions that promote true biologic fusion and structural stability for patients with sacropelvic disorders, with a commitment to driving value for patients, physicians, and shareholders [14] - The integration of SciVantage is expected to create a more diversified product offering, allowing the company to address various clinical needs in the sacropelvic region [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from the recent decline in revenue, anticipating a quick rebound as the integration with SciVantage progresses [28] - The company is optimistic about the upcoming launches of Catamaran SE and Symmetry Plus, which are expected to drive top-line growth [12][44] Other Important Information - The company ended the quarter with $7,800,000 in cash and no debt, providing flexibility to execute its strategic roadmap [12] - The company hosted 16 physician workshops in Q2 to support long-term adoption strategies and accelerate the learning curve for new users [7] Q&A Session Summary Question: How does the acquisition help achieve scale? - Management confirmed that the acquisition provides a pathway to scale and enhances access to hospital systems and contract groups, allowing for a more diversified product offering [17][20] Question: What is the timeline for filing audited financials for the acquisition? - The company indicated a 75-day post-close period to file the audited financials for SciVantage, expected by mid-October [24][27] Question: How should investors view Catamaran revenues in Q3 and Q4? - Management suggested that Q2 was disrupted by the acquisition process but expects a quick recovery in Catamaran revenues moving forward [28][30] Question: What is the reimbursement landscape for the new products? - The new products will participate in existing CPT codes for SI procedures, similar to the Catamaran system, with a focus on supporting technologies with data [40][41] Question: What is the expected impact of the Symmetry Plus launch? - The Symmetry Plus launch is anticipated to begin with alpha surgeries in October, with a full-scale launch expected early next year [44]